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There is insufficient data on patients with small body size to 
determine if this should be considered a risk factor for con-
tinuous-flow left ventricular assist device (CF-LVAD) support. 
We sought to evaluate survival outcomes, adverse events, and 
functional status of CF-LVAD patients with body surface area 
(BSA) <1.5 m2 in a large national registry. Adults with BSA < 1.5 
m2 (n = 128) implanted with a HeartMate II (HMII)-LVAD from 
the Interagency Registry for Mechanically Assisted Circulatory 
Support registry from April 2008 to December 2012 formed 
this cohort. Outcomes were compared with HMII bridge to 
transplant (BTT) and destination therapy (DT) post approval 
studies. The majority of patients were female (n = 106, 83%). A 
total of 64% (n = 82) were implanted for BTT and 36% (n = 46) 
for DT. The median BSA (range) was 1.44 (1.19–1.49) and 1.45 
(1.25–1.49) m2 for BTT and DT, respectively. Overall survival 1 
year post implant was 81% ± 5% for BTT and 84% ± 6% for 
DT. The most common adverse events for BTT and DT patients 
were bleeding (0.91, 0.88 events/patient year) and driveline 
infection (16%, 0.28 events/patient year). Six months post 
implantation, 87% of BTT and 77% of DT patients were New 
York Heart Association functional class I or II. Post implant sur-
vival, functional status improvement, and adverse event pro-
file for adult BTT and DT HMII patients with BSA < 1.5 m2 
are favorable and comparable with outcomes published in the 
overall patient population. ASAIO Journal 2016; 62:646–651.
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The landscape in the treatment of advanced heart failure is evolv-
ing rapidly with the increased use of continuous-flow left ven-
tricular assist devices (CF-LVADs) as a bridge to transplant (BTT) 
or as destination therapy (DT). In the latest Interagency Registry 
for Mechanically Assisted Circulatory Support (INTERMACS) 7th 
annual report, there have been more than 15,000 durable Food 
and Drug Administration (FDA)-approved devices implanted 
since June 2006.1 The International Society of Heart and Lung 
Transplantation reports that the percentage of patients bridged 
with a LVAD at the time of heart transplantation has increased 
from <20% in 2000 to more than 35% in 2011.2 Moreover, there 
is increased utilization of these devices as long-term permanent 
therapy or DT for advanced heart failure now accounting for up to 
40% of all indications for CF-LVAD implantation in recent years.3 
Outcomes in recent post FDA approval studies have been excel-
lent, with 85% survival of those remaining on CF-LVAD support 
1 year post implant for BTT patients and 74% for DT patients.4,5
Compared with the earlier technology of pulsatile displace-
ment pumps, CF-LVADs are smaller in size and can be implanted 
in the more restrictive anatomy of small patients. However, there 
is a paucity of data on the use and safety of CF-LVADs in adult 
patients with a small body surface area (BSA) < 1.5 m2. The 
HeartMate II clinical trial included a small body size cohort of 10 
patients which indicated similar outcomes in patients with BSA 
< 1.5 m2 and those more than 1.5 m2.6 To further address and 
clarify the use of CF-LVADs in adult patients with a small BSA 
in the post approval era, we sought to evaluate the survival out-
comes, adverse events, and functional status of patients with BSA 
< 1.5 m2 implanted with a CF-LVAD in a large national registry.
Methods
Patients
The INTERMACS registry was queried to identify all adult patients 
≥ 18 years of age with a BSA < 1.5 m2 who were implanted with 
the HeartMate II CF-LVAD (HMII, Thoratec Corporation, Pleasan-
ton, CA) between April 2008 and December 2012 (n = 128) for 
BTT (n = 82) or DT (n = 46) indications. Outcomes were com-
pared with the HMII BTT (April to August 2008; n = 169) and DT 
(January to September 2010; n = 247) post approval studies (PASs).
Data Collection
This was a retrospective registry study using the INTER-
MACS database. Data entry into the INTERMACS database 
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is voluntary and is specified by each participating center. The 
adverse events definitions and variables analyzed may be 
accessed via the INTERMACS website.7
Statistical Analysis
Continuous variables are presented as mean ± SD or median 
(range). Categorical variables are presented as proportions. Sur-
vival, adverse events, and quality of life were compared with 
the HMII BTT4 and DT5 PAS. Survival was evaluated using the 
Kaplan–Meier method. Comparison of survival between two 
groups was performed using the log-rank test. Adverse events are 
presented as both percentages and event rates (events per patient 
year of support; eppy). Comparisons of adverse event rates were 
performed using Cochran–Mantel–Haenszel statistics. All statisti-
cal comparisons were two sided with a significance level at p < 
0.05. Statistical analyses were performed with SigmaPlot (Cranes 
Software, Chicago, IL) and SAS (SAS Institute, Inc., Cary, NC).
Results
Baseline Characteristics
Table 1 shows the baseline characteristics of the small BSA 
< 1.5 m2 cohort stratified by BTT and DT. The most striking 
demographic characteristic unique to this patient population is 
that the majority of the patients (80% BTT and 87% DT) were 
female. The majority of patients were implanted as INTERMACS 
profile 2–3 (64% BTT and 63% DT) and New York Heart Asso-
ciation (NYHA) Class IV (76% BTT and 85% DT). The median 
(range) BSA was 1.44 m2 (1.19–1.49) and 1.45 m2 (1.25–1.49) 
for BTT and DT patients, respectively. Age was greater in the 
DT group with 76% at least 60 years old compared with 40% 
for BTT. Tables 2 and 3 show the baseline characteristics of the 
HMII BTT and DT PAS cohorts, respectively. Females made up 
22% and 17% of the BTT and DT PAS cohorts, respectively. 
The median BSA was 2.03 ± 0.25 and 2.01 ± 0.29 m2 for the 
BTT and DT PAS cohorts, respectively.
Outcomes
Survival.  The survival of the small BSA cohort was compared 
with the survival of the HMII BTT4 and DT5 PASs (Figures 1 and 
2). For the BTT population, the 6 month and 1 year post im-
plant survival of the small BSA cohort was 84% ± 4% and 81% 
± 5%, respectively, which were similar to and not statistically 
different from the 6 month and 1 year post implant survival in 
the post approval BTT population (90% ± 2% and 84% ± 3%, 
respectively; p = 0.367). For the DT population, the 1 and 2 
year post implant survival of the small BSA cohort was 84% ± 
Table 1.  Baseline Characteristics: Small BSA Cohort
Characteristic BTT (n = 82) DT (n = 46)
Age (year)
  <40 20 (24%) 2 (4%)
  40–59 29 (35%) 9 (19%)
  ≥60 33 (40%) 35 (76%)
Female sex (%) 66 (80%) 40 (87%)
Race
  White 51 (62%) 30 (65%)
  Black 15 (18%) 1 (2%)
  Asian/American Indian 6 (7%) 9 (20%)
  Unknown/other 10 (13%) 6 (13%)
INTERMACS profiles
  Profile 1 18 (22%) 5 (11%)
  Profile 2–3 52 (64%) 29 (63%)
  Profile 4–7 10 (12%) 12 (26%)
Ischemic etiology (%) 26 (32%) 20 (43%)
NYHA class IV (%) 62 (76%) 39 (85%)
Body surface area (m2) (median 
[range])
1.44 [1.19–1.49] 1.45 [1.25–1.49]
Weight (kg) 47 [35–53] 49 [39–54]
BSA, body surface area; INTERMACS, Interagency Registry for 
Mechanically Assisted Circulatory Support; NYHA, New York Heart 
Association.
Figure 1. Kaplan-Meier survival for small BSA BTT patients compared to post approval BTT study. BSA, body surface area; BTT, bridge 
to transplant. 
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6% and 79% ± 8%, respectively, and trended higher but was 
not statistically different from the 1 and 2 year post implant 
survival in the post approval DT population (74% ± 3% and 
61% ± 3%, respectively; p = 0.105).
Adverse Events.  The adverse event rates for the small BSA 
cohort are similar to the BTT and DT post approval patients 
(Tables 4 and 5, respectively). However, in the BTT population, 
bleeding was significantly lower in the small BSA cohort (0.91 
vs. 1.44 eppy; p = 0.010). In DT patients, hemolysis occurred 
more frequently in the small BSA patients (0.16 vs. 0.06 eppy; 
p = 0.014).
Functional Status.  Both BTT and DT small BSA patients 
had a marked improvement in NYHA Classification. Before 
implant, no patients reported NYHA Class I/II symptoms. At 
6 months post implant, more than 75% of small BSA patients 
had improved to NYHA class I/II with sustained improvement 
through 12 months (Figure 3A, B).
Discussion
This study represents the largest cohort of adult patients with 
a BSA < 1.5 m2 implanted with a CF-LVAD and support the use 
of CF-LVAD therapy in this patient population.
The post implant survival of small BSA patients are com-
parable with the published HMII post approval BTT and DT 
studies where the mean BSA was 2.03 ± 0.25 and 2.01 ± 0.29 
m2, respectively.4,5 The post implant survival of the small BSA 
BTT cohort was 84% ± 4% and 81% ± 5% at 6 months and 
Figure 2. Kaplan-Meier survival for small BSA DT patients compared to postapproval DT study. BSA, body surface area; DT, destination 
therapy. 
Figure 3. A: NYHA classification of BTT patients pre- and post-LVAD implant. B: NYHA classification of DT patients pre and post LVAD 
implant. BTT, bridge to transplant; DT, destination therapy; LVAD, left ventricular assist device; NYHA, New York Heart Association.
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1 year, respectively. Although not statistically significant, the 
small BSA DT cohort had improved 1 and 2 year post implant 
survival compared with the DT PAS (84% ± 6% vs. 74% ± 3% 
and 79% ± 8% vs. 61% ± 3%, respectively; p = 0.105).
The adverse event profile of the small BSA patients is 
equally as comparable with the post approval HMII BTT and 
DT studies (Tables 4 and 5). For the BTT population, the small 
BSA cohort had adverse event rates that were not statistically 
different from the HMII BTT PAS for all the major adverse 
events rates studied, with the exception that there was less 
bleeding noted in the small BSA cohort (0.91 vs. 1.44 eppy). 
Similarly, the adverse event profile for the DT population was 
not dissimilar from the post approval DT cohort, although 
more hemolysis was noted in the small BSA cohort (0.16 vs. 
0.06 eppy). The reason for a higher incidence of hemolysis in 
the small BSA cohort is unclear. Increased hemolysis may be 
associated with the cannula position in a small BSA patient, 
smaller relative circulating blood volume passing through the 
rotor, or other factors all of which require further investiga-
tion. However it does not appear to be related to thrombus, 
which was similar at 0.03 to 0.04 eppy between cohorts, and 
stroke at 0.04 eppy was actually trending to be lower in the 
smaller patients but this did not reach statistical significance.
Paralleling comparable post implant survival outcomes and 
adverse event profiles of the small BSA patients is the marked 
improvement in NYHA functional class with the majority of 
patients reporting class I/II post implant, suggesting that the 
small BSA patients enjoy not only morbidity and mortality 
benefits but also improved quality of life with LVAD therapy.
The US clinical trial of the HM II also studied two small BSA 
patient (BSA < 1.5) cohorts, one for DT (n = 24) and one for 
BTT (n = 10), which were analyzed separately in the trial. The 
BTT cohort was composed of 10 females and was published 
in the device labeling.6 All small BSA patients survived to 
180 days post implant with 86% improving from NYHA class 
IV to class I/II after 3 months. Six minute walk distance also 
increased an average of 230 m in the small BSA cohort versus 
247 m in the primary study cohort. Adverse event rates were 
similar to those measured in the primary study cohort. Patients 
with small body size were comparable with larger patients in 
the clinical study; however, the number of small BSA patients 
was too few to make definitive conclusions.
A recent report by Cabrera et al.8 utilizing the INTERMACS 
registry compared outcomes of 28 pediatric patients aged 11 
Table 2.  Baseline Characteristics: HMII BTT PAS Cohort
Characteristic BTT (n = 169)
Age (year)
  <40 26 (15%)
  40–59 81 (48%)
  ≥60 59 (35%)
Female sex (%) 38 (22%)
Race
  White 125 (74%)
  Black 29 (17%)
  Unknown/other 15 (9%)
INTERMACS profiles
  Profile 1 41 (24%)
  Profile 2–3 96 (57%)
  Profile 4–7 32 (19%)
Body surface area (m2) (median ± SD) 2.03 ± 0.25
BTT, bridge to transplant; HMII, HeartMate II; INTERMACS, 
Interagency Registry for Mechanically Assisted Circulatory Support; 
PAS, post approval study.
Table 3.  Baseline Characteristics: HMII DT PAS Cohort
Characteristic DT (n = 247)
Age (years)
  <40 6 (2%)
  40–59 69 (28%)
  ≥60 172 (70%)
Female sex (%) 43 (17%)
Race
  White 185 (75%)
  Black 45 (18%)
  Unknown/other 17 (7%)
INTERMACS profiles
  Profile 1 18 (22%)
  Profile 2–3 52 (64%)
  Profile 4–7 10 (12%)
Ischemic etiology (%) 140 (57%)
NYHA class IV (%) 196 (79%)
Body surface area (m2) (median ± SD) 2.01 ± 0.29
Weight (kg) (median ± SD) 85 ± 22
DT, destination therapy; HMII, HeartMate II; INTERMACS, 
Interagency Registry for Mechanically Assisted Circulatory Support; 
NYHA, New York Heart Association; PAS, post approval study.
Table 4.  Adverse Events: BTT
HMII Patients With a Small BSA (n = 82) 
(Total Duration: 107.9 Patient Years)
HMII BTT Post Approval Study (n = 169) 
(Total Duration: 142 Patient Years) p
% Patients
Events (Events/Patient 
Year) % Patients
Events (Events/Patient 
Year)  
Bleeding 35 (43%) 98 (0.91) 75 (44%) 204 (1.44) 0.010
Explant due to device thrombosis 1 (1%) 1 (0.01) NR NR NR
Hemolysis 5 (6%) 6 (0.06) 5 (3%) 5 (0.04) 0.458
Hepatic dysfunction 8 (10%) 8 (0.07) 11 (7%) 12 (0.08) 0.783
Any infection 33 (40%) 112 (1.04) 78 (46%) 142 (1.00) 0.836
  Drive line infection 13 (16%) 30 (0.28) 30 (18%) 45 (0.32) 0.626
  Pump pocket infection 1 (1%) 1 (0.01) 3 (1.8%) 3 (0.02) 0.467
Stroke 7 (9%) 7 (0.06) 11 (7%) 11 (0.08) 0.723
Renal dysfunction 11 (13%) 11 (0.10) 17 (10%) 19 (0.13) 0.496
Right heart failure 9 (11%) 12 (0.11) 25 (15%) 26 (0.18) 0.177
BSA, body surface area; BTT, bridge to transplant.
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to 18 years compared with young adults aged 19 to 39 years 
implanted with the HMII. At 6 months, the composite of sur-
vival to transplantation, ongoing support, or recovery was 96% 
for the pediatric group, not dissimilar to the young adult group 
(p = 0.330). The median BSA for the pediatric group was 1.91 
m2 (1.47–2.65).
Interestingly, the results of the Japanese HMII prospective BTT 
trial were recently published.9 The six patients enrolled in this 
study had a mean BSA of 1.58 ± 0.17 m2. All patients were ino-
trope dependent and failing medical management at baseline. 
Although a small trial, at 6 months post implant, there were no 
deaths and all patients were alive with ongoing support. Func-
tional status assessed by the 6 minute walk distance increased 
from 268 ± 92 m at baseline to 399 ± 105 m, and 100% of the 
patients were reported to be NYHA class I/II in follow-up. All 
the six patients eventually were successfully transplanted.
Unlike previous studies, but similar to the small patient 
cohort in the US clinical trial, this report is unique in that the 
study population is predominantly female. The majority of 
clinical trials and investigations in heart failure have tradition-
ally been comprised of predominantly male populations. In 
the mechanical circulatory support literature, the female sex 
is particularly underrepresented. This is especially true histori-
cally with the use of the first-generation pulsatile displacement 
pumps, where smaller anatomies were physically unable to 
accommodate the larger devices. A recent single center study 
looked at sex-specific outcomes in the CF-LVADs era.10 Their 
study population included 130 patients, 35 (27%) of whom 
were female. The investigators found comparable short and 
mid-term post implant survival outcomes, hospital length of 
stay, readmissions rates, and post operative complications 
between males and females.
Boyle et al.11 retrospectively analyzed the pre operative risks 
for bleeding and stroke during CV-LVAD support in the HMII 
BTT and DT clinical trials. Of 956 patients, 220 (23%) were 
female. The authors found an increased incidence of throm-
botic and hemorrhagic events in female patients compared 
with male patients. In this report, 83% of the study popula-
tion was female, and with comparable post implant survival 
outcomes and adverse event rates matching the post approval 
LVAD studies, it may be suggested that females benefit as much 
from CF-LVAD therapy as their male counterparts.
Limitations
This study has several important limitations. The PASs 
included the small BSA cohort but because the majority of 
patients in the PAS had a BSA > 1.5 m2, the impact of this 
inclusion would not be clinically significant. The BTT and DT 
PAS cohorts were not implanted during the same time-frame 
which may have influenced outcomes as management strate-
gies are expected to improve with time and experience. The 
INTERMACS database was designed as a registry and not 
for the purpose of analyzing outcomes in small BSA patients 
implanted with CF-LVADs. Furthermore, the survival outcomes 
and adverse event rates of the small BSA patients compared 
with the post approval BTT and DT studies were not risk 
adjusted.
In conclusion, this study represents the largest cohort of 
adult patients analyzed with a small BSA < 1.5 m2 receiving a 
CF-LVAD. The majority of the patient population was female. 
with comparable post implant survival outcomes and adverse 
event rates comparable with the published post approval BTT 
and DT studies, this study supports the use of CF-LVADs as BTT 
or DT in patients with a small BSA < 1.5 m2.
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